Published in

Elsevier, Annals of Oncology, 7(22), p. 1561-1570, 2011

DOI: 10.1093/annonc/mdq624

Links

Tools

Export citation

Search in Google Scholar

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Journal article published in 2011 by M. A. Vollebergh, E. H. Lips, P. M. Nederlof, L. F. A. Wessels, M. K. Schmidt ORCID, E. H. van Beers, S. Cornelissen, M. Holtkamp, F. E. Froklage, E. G. E. de Vries, J. G. Schrama, J. Wesseling, M. J. van de Vijver, H. van Tinteren ORCID, M. de Bruin and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background: Breast cancer cells deficient for BRCA1 are hypersensitive to agents inducing DNA double-strand breaks (DSB), such as bifunctional alkylators and platinum agents. Earlier, we had developed a comparative genomic hybridisation (CGH) classifier based on BRCA1-mutated breast cancers. We hypothesised that this BRCA1-likeCGH classifier could also detect loss of function of BRCA1 due to other causes besides mutations and, consequently, might predict sensitivity to DSB-inducing agents.